Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
Rev. bras. hematol. hemoter
;
37(6): 406-413, Oct.-Dec. 2015. tab, graf
Artículo
en Inglés
| LILACS
| ID: lil-769968
ABSTRACT
Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Inmunofenotipificación
/
Neoplasia Residual
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Citometría de Flujo
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
Rev. bras. hematol. hemoter
Asunto de la revista:
Hematología
Año:
2015
Tipo del documento:
Artículo
País de afiliación:
Brasil
Institución/País de afiliación:
Diagnósticos da América (DASA)/BR
/
Centro de Hematologia e Hemoterapia de Santa Catarina/BR
/
Fundação Amaral Carvalho/BR
/
Universidade Federal de São Paulo/BR
/
Universidade Federal do Paraná/BR
Similares
MEDLINE
...
LILACS
LIS